Sign Out
In clinical trials, participants who received up to 2 times the recommended dose of COMIRNATY did not have an increase in reactogenicity or adverse events.
In post-authorisation experience, there have been reports of higher than recommended doses of COMIRNATY. In general, adverse events reported with overdoses have been similar to the known adverse reaction profile of COMIRNATY.
In the event of overdose, monitoring of vital functions and individualised symptomatic treatment is recommended.
Continue with Google